Table 2.
Levels of spike (S) antibodies 14+ days after dose 2 COVID-19 vaccination in N-negative individuals by risk group status: N samples,% positive, median response and geometric mean (GM) ratio of responses.
| absence / presence in risk group | N | n pos (%) | median (IQR)1 | adjusted GM ratio (95% CI)2 |
|---|---|---|---|---|
| Astra Zeneca AZD1222: risk groups | ||||
| not CHD | 955 | 951 (100%) | 782 (401 - 1536) | 1 (ref) |
| CHD | 303 | 301 (99%) | 719 (273 - 1552) | 0.88 (0.74 - 1.04) |
| not diabetes | 1034 | 1028 (99%) | 774.5 (364 - 1533) | 1 (ref) |
| diabetes | 224 | 224 (100%) | 714 (333 - 1580.5) | 1.02 (0.85 - 1.23) |
| not neurological | 1149 | 1144 (100%) | 767 (360 - 1547) | 1 (ref) |
| neurological | 109 | 108 (99%) | 708 (349 - 1494) | 1.05 (0.82 - 1.34) |
| not chronic kidney | 1121 | 1117 (100%) | 781 (377 - 1552) | 1 (ref) |
| chronic kidney | 137 | 135 (99%) | 628 (237 - 1297) | 0.75 (0.6 - 0.95)* |
| not morbid obesity | 1197 | 1192 (100%) | 759 (360 - 1530) | 1 (ref) |
| morbid obesity | 61 | 60 (98%) | 862 (337 - 2217) | 1.09 (0.79 - 1.52) |
| not chronic respiratory | 1164 | 1159 (100%) | 779 (375 - 1543.5) | 1 (ref) |
| chronic respiratory | 94 | 93 (99%) | 517 (190 - 1496) | 0.59 (0.45 - 0.77)⁎⁎ |
| not immunosuppressed | 1169 | 1164 (100%) | 777 (366 - 1540) | 1 (ref) |
| immunosuppressed | 89 | 88 (99%) | 631 (198 - 1479) | 0.7 (0.54 - 0.92)* |
| not chronic liver | 1205 | 1199 (100%) | 767 (362 - 1551) | 1 (ref) |
| chronic liver | 53 | 53 (100%) | 544 (320 - 1431) | 0.8 (0.57 - 1.14) |
| not severe asthma | 1216 | 1210 (100%) | 763 (360 - 1543.5) | 1 (ref) |
| severe asthma | 42 | 42 (100%) | 810.5 (339 - 1404) | 1.11 (0.75 - 1.64) |
| Astra Zeneca AZD1222: risk status | ||||
| not in any risk group | 569 | 568 (100%) | 845 (449 - 1678) | 1 (ref) |
| any risk group (non-shielding) | 640 | 635 (99%) | 683 (300 - 1464.5) | 0.74 (0.64 - 0.86)⁎⁎ |
| shielding | 49 | 49 (100%) | 801 (359 - 1722) | 0.87 (0.6 - 1.26) |
| Pfizer Bio N-Tech BNT162b2: risk groups | ||||
| not CHD | 779 | 774 (99%) | 2934 (1378 - 5861) | 1 (ref) |
| CHD | 496 | 494 (100%) | >2500 (804 - 4895.5) | 1.07 (0.91 - 1.26) |
| not diabetes | 1002 | 996 (99%) | 2763.5 (1234 - 5669) | 1 (ref) |
| diabetes | 273 | 272 (100%) | >2500 (752 - 4798) | 0.78 (0.65 - 0.94)⁎⁎ |
| not neurological | 1084 | 1079 (100%) | 2638 (1192 - 5629) | 1 (ref) |
| neurological | 191 | 189 (99%) | >2500 (838 - 4792) | 0.91 (0.74 - 1.12) |
| not chronic kidney | 1014 | 1010 (100%) | 2845 (1273 - 5807) | 1 (ref) |
| chronic kidney | 261 | 258 (99%) | 2402 (739 - 4204) | 0.92 (0.76 - 1.11) |
| not morbid obesity | 1215 | 1208 (99%) | 2503 (1070 - 5417) | 1 (ref) |
| morbid obesity | 60 | 60 (100%) | 3812.5 (1789.5 - 12,600) | 0.92 (0.64 - 1.3) |
| not chronic respiratory | 1161 | 1157 (100%) | 2657 (1149 - 5694) | 1 (ref) |
| chronic respiratory | 114 | 111 (97%) | 2312.5 (552 - 4032) | 0.64 (0.49 - 0.83)⁎⁎ |
| not immunosuppressed | 1161 | 1159 (100%) | 2788 (1370 - 5709) | 1 (ref) |
| immunosuppressed | 114 | 109 (96%) | 767 (202 - 2645) | 0.23 (0.18 - 0.29)⁎⁎ |
| not chronic liver | 1212 | 1205 (99%) | 2524 (1081 - 5487.5) | 1 (ref) |
| chronic liver | 63 | 63 (100%) | 2815 (1591 - 6193) | 1.31 (0.93 - 1.84) |
| not severe asthma | 1237 | 1230 (99%) | 2569 (1097 - 5521) | 1 (ref) |
| severe asthma | 38 | 38 (100%) | >2500 (1149 - 4922) | 1.02 (0.65 - 1.59) |
| Pfizer Bio N-Tech BNT162b2: risk status | ||||
| not in any risk group | 373 | 373 (100%) | 3576 (1893 - 6684) | 1 (ref) |
| any risk group (non-shielding) | 836 | 829 (99%) | >2500 (880 - 5072) | 0.74 (0.62 - 0.88)⁎⁎ |
| shielding | 66 | 66 (100%) | 2064 (547 - 3996) | 0.71 (0.49 - 1.04) |
⁎
statistically significant at 5% level,.
⁎⁎
statistically significant at 1% level.
1
some S levels were capped at 2500, hence some results can only be given as >2500.
2
adjusted for age, sex, days since dose and dosing schedule.